Non-Hodgkin lymphoma (NHL) is among the most common cancers in the United States. In 2020, an estimated 77,240 Americans will be diagnosed with the disease and about 20,000 people will die from it.1 Seventy-two percent of patients live for at least 5 years after diagnosis.2 However, the success of treatment varies widely across the many subtypes of NHL. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the most common subtype, have a 5-year survival rate of 63% for all disease stages combined. By contrast, follicular lymphoma (FL) has a 5-year survival rate of 88% for all stages combined. Patients with mantle cell lymphoma, one of the more difficult-to-treat subtypes, have an average survival time of less than 5 years.3
But the treatment landscape is transforming across the entire spectrum of NHL. Novel immunotherapies and small molecule inhibitors are offering both previously treated and untreated patients entirely new options and new combinations. At the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, researchers led by Jeremy Abramson, of Massachusetts General Hospital in Boston, provided a compelling overview of these new and upcoming treatments.4 Their overview, published in the ASCO Educational Book, offered a detailed and vital look at the present and future of NHL treatment.
CAR T-cell immunotherapy has been hailed as a major game-changer for some blood cancers.5 For aggressive B-cell lymphomas, such as DLBCL, anti-CD19 chimeric antigen receptor T cells (CAR-T) are a new option for patients who have relapsed following chemoimmunotherapy or autologous stem cell transplant (ASCT). For this patient group, which has a median overall survival of about 4 months, anti-CD19 CAR-T agents have elicited durable remissions in about 40% of patients.5-7 Clinical trial data has led to the approval of axicabtagene, ciloleucel, and tisagenlecleucel by both the US Food and Drug Administration and the European Medicine Agency. CAR T-cells offer curative intent therapy to patients with relapsed DLBCL who are not eligible for stem cell transplant, Dr Abramson told Cancer Therapy Advisor. Previously these patients only had palliative options available.
Some clinicians envision CAR-T as a potential first-line therapy for patients with DLBCL who relapsed after first-line chemoimmunotherapy. These patients, noted Anton Hagenbeek, MD, PhD, professor of Hematology at Amsterdam University Medical Centers, who was not involved with the review paper, represent one of the highest unmet needs in the treatment of lymphoma to date. And Helen Heslop, MD, who directs the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, Texas, noted that trials for first-line CAR-T therapy are already underway in acute lymphoblastic leukemia. Not everyone sees this potential. First-line treatment in NHL is generally very effective and much less expensive than CAR T-cells, explained Edward Copelan, MD, who chairs the Department of Hematologic Oncology and Blood Disorders at Carolinas Healthcare System in Charlotte, North Carolina, and who was not an author of the review. Though Dr Copelan emphasized that patients at extremely high risk of relapse following standard immunochemotherapy may respond well to CAR-T therapy.
Dr Abramson and co-authors highlighted a difficult conundrum with regard to DLBCL. Although the addition of rituximab to cyclophosphamide, doxorubicin, hydrochloride, and vincristine sulfate (CHOP) chemotherapy is curative for most patients, the number of patients who may be cured after relapse has declined. Thus improvements in second-line therapy are desperately needed. Several clinical trials are currently evaluating anti CD19 CAR-T for primary refractory or early relapsed aggressive B-cell lymphoma compared with traditional salvage therapy or ASCT. The same approach is being studied for relapsed DLBCL patients who are not transplant candidates.
Whether CAR-T therapy will find a place on the first line of care is another current question. The cost and logistics of CAR-T therapy make it unlikely that this approach will replace R-CHOP as the standard initial treatment, Dr Abramson and colleagues noted. I do not think CAR T-cells will replace frontline chemotherapy, Dr Abramson said. However, the authors note that for patients who do not respond well to initial treatment, such an approach may make sense a possibility that is now being examined in the clinical trial setting. Dr Hagenbeek is more certain about the first-line role for CAR-T therapy, based on the dismal prognosis of DLBCL that is refractory to R-CHOP.
On the subject of CAR-T therapy as first-line therapy, the authors pay special attention to so-called double-hit lymphomas (DHLs), also known as double expressor lymphomas. According to a multicenter study published in 2017, R-CHOP is curative for more patients than conventional wisdom has held.9 Clinical trials are currently investigating the use of anti-CD19 CAR-T early for patients who consistently test positive for disease on PET scans during initial therapy, though Dr Abramson and colleagues call for caution with this approach because the prognostic value of PET/CT scans is controversial. Dr Hagenbeek is optimistic about the potential for CAR-T therapy to improve the prognosis for patients with double- and even triple-hit lymphomas, if applied in the first complete, PET-negative metabolic remission. Because these patients have a relatively small tumor load, this approach could, said Dr. Hagenbeek, completely eradicate minimal residual disease. Its the double-hit patients who Dr Copelan sees as the likeliest candidates for first-line CAR T-cell treatment.
Continued here:
- Experimental cell therapy trial treats first Sjgrens disease patient - University of Wisconsin School of Medicine and Public Health - February 11th, 2025
- Stem Cell Therapy Market Types, Applications, Share, Growth - openPR - February 6th, 2025
- Placental Stem Cell Therapy Solution Market Size And Booming - openPR - February 6th, 2025
- Revitalizing Health with Stem Cell Therapy: A Groundbreaking Path To Longevity and Wellness - openPR - February 4th, 2025
- Gene therapy offers new hope for sickle cell disease patients - Open Access Government - February 4th, 2025
- Scientists trial implant to patch up the heart - BBC.com - February 2nd, 2025
- Cell Therapy Market Size is Projected to Reach USD 33.93 - GlobeNewswire - January 28th, 2025
- Meet the California Institute Pushing Stem Cell & Gene Therapy Research: Part 3 - The Medicine Maker - January 28th, 2025
- Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium 2025 - The Eastern... - January 28th, 2025
- Beyond the Lab: Stem cell research - Drug Target Review - January 25th, 2025
- Asia Pacific Stem Cell Therapy Market to Reach US$ 4,075.75 Million by 2033 with a Robust CAGR of 10.29% - openPR - January 25th, 2025
- Exciting data: S.Biomedics preps US IND of PD cell therapy - BioWorld Online - January 25th, 2025
- $24.85 Billion Cell Therapy Market Forecast by 2032 (CAGR 20.4%) - openPR - January 25th, 2025
- Stem Cell Therapy Market Expected to Expand at a Steady 2025-2032 - openPR - January 25th, 2025
- Regenerative Medicine Market to receive overwhelming hike US$ 164.9 billion in Revenues by 2032, Growing at a CAGR of 23.30% From 2024 to 2032 -... - January 25th, 2025
- Alternative medicine fans see RFK Jr. as a hero. The fields skeptics worry. - The Washington Post - January 23rd, 2025
- U.S. PRP and Stem Cell Alopecia Treatment Market Analysis 2025-2030 by Treatment, Indication, and End-use - Androgenic Alopecia Dominated the Market... - January 23rd, 2025
- The Future of Regenerative Medicine Lies in the Hands of Chiropractors - Dynamic Chiropractic - January 23rd, 2025
- Stem Cell Therapy Industry Dynamics and Contributions by RTI - openPR - January 21st, 2025
- Stem Cells Market to Reach USD 44.27 Billion by 2033, Driven by Expanding Applications and Innovations - openPR - January 21st, 2025
- Organoids at the Forefront Innovations in Stem Cell Research and Precision Medicine - openPR - January 21st, 2025
- The promising future of regenerative medicine - Yahoo Finance - January 17th, 2025
- An earful of gill: USC Stem Cell study points to the evolutionary origin of the mammalian outer ear - EurekAlert - January 11th, 2025
- Aspen Partners with Mytos to Automate Stem Cell Production for Parkinsons Therapy - Genetic Engineering & Biotechnology News - January 9th, 2025
- School of Medicine professor receives grant to study improved cancer treatments - Mercer University - January 9th, 2025
- Meet CIRM: the California Institute Pushing Stem Cell and Gene Therapy Research: Part 1 - The Medicine Maker - January 7th, 2025
- Regenerative Medicine Market to Experience Significant Growth, Projected to Reach $183.08 Billion by 2031. - openPR - January 7th, 2025
- Stem-cell therapies that work: 10 Breakthrough Technologies 2025 - MIT Technology Review - January 5th, 2025
- 1st stem cell therapy, new HIV drug approved - ecns - January 5th, 2025
- Science fiction turned reality? Stem cell therapy set to repair child's heart - Ynetnews - January 3rd, 2025
- Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology - The Manila Times - January 1st, 2025
- Allogeneic Stem Cell Transplantation Market Size to Expand Lucratively by 2031 - openPR - January 1st, 2025
- Apoptotic clearance by stem cells: molecular mechanisms for recognition and phagocytosis of dead cells - Nature.com - December 30th, 2024
- Why Medical Tourists are Choosing Mexico: The Affordable Alternative for Advanced Stem Cell Treatments - openPR - December 30th, 2024
- Induced Pluripotent Stem Cells (iPSC) Production Market: Trends, Growth, and the Role of AI - openPR - December 30th, 2024
- Stem cells 'instructed' to form specific tissues and organs - New Atlas - December 28th, 2024
- Stem Cell Transplantation Still the Main Treatment Option for Beta-Thalassemia - Medpage Today - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Galveston County Daily News - December 28th, 2024
- Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine - Voice Of Alexandria - December 28th, 2024
- U.S. Stem Cell Therapy Market Revenue to Attain USD 17.70 Bn by 2033 - Precedence Research - December 27th, 2024
- Here are some biggest medical breakthroughs of 2024 - Medical Buyer - December 27th, 2024
- Researchers from Korea University explore how ascorbic acid and FGF4 revolutionize regenerative medicine - EurekAlert - December 27th, 2024
- Regenerative Medicine Market to Skyrocket to USD 73,084.2 Million by 2033 at a 18.5% of CAGR - openPR - December 27th, 2024
- Stem cell therapy to correct heart failure in children could 'transform lives' - Fox News - December 25th, 2024
- Advancing type 1 diabetes therapy: autologous islet transplant breakthrough - Nature.com - December 25th, 2024
- Stem Cell Therapy Market to Triple in Value, Reaching USD 52.1 Billion by 2034 at a 12.1% of CAGR - openPR - December 25th, 2024
- Stem-cell therapies: A breakthrough in treating parkinson's, cancer, diabetes, and more - The Business Standard - December 25th, 2024
- Replay 2024 : 6 Biggest Medical Breakthroughs Of 2024 - NewsX - December 25th, 2024
- Tumbling stem cells? Watch how movement plays a part in their fate - Scope - December 20th, 2024
- SCD patients free of VOEs after treatment with gene-editing therapy - Sickle Cell Disease News - December 20th, 2024
- Japan's Sumitomo to establish regenerative medicine and cell therapy joint venture - BSA bureau - December 20th, 2024
- Brain cells remain healthy after a month on the International Space Station, but mature faster than brain cells on Earth - EurekAlert - December 19th, 2024
- Reindeers Pave the Way for Regenerative Medicine - The Scientist - December 19th, 2024
- Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA (ibrutinib) in adult... - December 19th, 2024
- What Role Does Regenerative Medicine Play In The Management Of Type 1 And Type 2 Diabetes? - TheHealthSite - December 19th, 2024
- World's 1st Stem Cell Book on Animals, Reveals How to Extend the Lives of Pets - PR Newswire - December 17th, 2024
- Accelerated Biosciences and Stemmatters Collaborate to Offer iPSC Derived from Human Trophoblast Stem Cells - Business Wire - December 17th, 2024
- Stem Cells: Hope on the Horizon for Preterm Babies - Monash University - December 17th, 2024
- Stem Cell Transplant Offers No Difference in OS or PFS in Mantle Cell Lymphoma Compared with Maintenance Therapy Alone - OncoZine - December 17th, 2024
- Inside One Mans Journey with Multiple Myeloma - Men's Health - December 15th, 2024
- Stem Cells Market Size to Reach USD 48.83 Billion By 2034 - Exclusive Report by Precedence Research - BioSpace - December 13th, 2024
- Treating Heart Defects with Tissue-engineered Vascular Conduits - Yale School of Medicine - December 13th, 2024
- Tom Curry: England flanker has stem-cell therapy in bid to make 2027 World Cup - BBC.com - December 13th, 2024
- Stem Cell Manufacturing Market Dynamics Key Drivers Challenges and Technological Innovations - Set to reach USD 26.6 billion by 2033 - PharmiWeb.com - December 13th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of USD 54.7 Bn By 2033, At 12.6% CAGR: Dimension Market Research - The Manila Times - December 13th, 2024
- Stem cell transplantation could save the coral reefs - Ynetnews - December 13th, 2024
- Vitrification Market | Driving Innovations in Cryopreservation for Fertility Treatments and Regenerative - EIN News - December 13th, 2024
- Workshop on Regenerative Medicine concludes at SKUAST-K - Greater Kashmir - December 13th, 2024
- High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma - News-Medical.Net - December 11th, 2024
- Stem Cell Therapy Market Is Expected To Reach Revenue Of - GlobeNewswire - December 11th, 2024
- Stem Cell Therapy Market to Worth Over US$ 2,612.92 Million By 2033 | Astute Analytica - GlobeNewswire - December 11th, 2024
- Changes in Blood Cell Production Over the Lifetime | Newswise - Newswise - December 7th, 2024
- Study reveals how stem cells respond to environmental signals, with implications for IBD and colorectal cancer - Medical Xpress - December 5th, 2024
- Stem cell therapy TED-A9 showing safety and early efficacy in trial - Parkinson's News Today - December 5th, 2024
- BMP-2 loaded scaffold for stem and immune cell recruitment in therapeutic applications - News-Medical.Net - December 5th, 2024
- Stem Cell Treatment May Help To Cure Vision Loss - Anti Aging News - December 5th, 2024
- BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024... - December 3rd, 2024
- Stem Cell Therapy Strategic Business Report 2024 - - GlobeNewswire - December 3rd, 2024
- Enhancing the efficacy of cell transplantation therapy for stroke or traumatic brain injury - Medical Xpress - December 1st, 2024
- Apheresis in Cellular Therapies: Unlocking Quality for CAR T and Stem Cell Treatments, Upcoming Webinar Hosted by Xtalks - PR Web - November 29th, 2024
Recent Comments